A Multicenter, Open Label, Randomized, Parallel Group Clinical Study Designed To Examine The Efficacy And Safety Of TLY-001 In Both Kashayam And Kashayam Tablet Form Twice Daily Oral Dose In 150 Patients With Newly Diagnosed Type 2 Diabetes Mellitus Over A Period Of Ninety (90) Days.

Clinfound Clinical Research Services PvtLtd0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with FBS >= 130 mg/dl to <= 250 mg/dl.
•2.Patients with BMI Ë? 45 kg/m2 .
•3.Newly detected Type 2 Diabetes Mellitus (not more than 1 year).
•4.The patient with the ability to understand and provide written informed consent form, which must have been obtained prior to screening.
•5.Patients willing to comply with protocol requirements

•1.Patients with Type 1 Diabetes or secondary form of Diabetes
•2.Pregnant, breast feeding, or planning a pregnancy.
•3.Patient with history of treatment with Insulin
•4.Patient with history of treatment with any antihyperglycaemic agent.
•5.Active, uncontrolled, or clinically significant diseases or disorders of the heart, lung, kidney, GI tract, or central nervous system.
•6.Known to have AIDS or HIV positive.

发起方

Clinfound Clinical Research Services PvtLtd